Symbols / SMMT Stock $16.87 -7.00% Summit Therapeutics Inc.

Healthcare • Biotechnology • United States • NGM
SMMT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert W. Duggan
Exch · Country NGM · United States
Market Cap 13.09B
Enterprise Value 12.52B
Income -1.21B
Sales —
FCF (ttm) 69.88M
Book/sh 0.85
Cash/sh 0.77
Employees 265
Insider 10d —
IPO Mar 05, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -14.64
PEG —
P/S —
P/B 19.85
P/C —
EV/EBITDA -10.24
EV/Sales —
Quick Ratio 7.19
Current Ratio 7.41
Debt/Eq 3.67
LT Debt/Eq —
EPS (ttm) -1.59
EPS next Y -1.15
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-04-30
ROA -148.16%
ROE -270.95%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 776.16M
Shs Float 134.66M
Insider Own 82.64%
Instit Own 15.83%
Short Float 21.65%
Short Ratio 7.57
Short Interest 29.19M
52W High 30.98
vs 52W High -45.55%
52W Low 13.83
vs 52W Low 21.98%
Beta -1.25
Impl. Vol. 71.97%
Rel Volume 0.81
Avg Volume 3.31M
Volume 2.67M
Target (mean) $29.70
Tgt Median $32.90
Tgt Low $11.84
Tgt High $44.00
# Analysts 14
Recom Buy
Prev Close $18.14
Price $16.87
Change -7.00%
About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.70
Mean price target
2. Current target
$16.87
Latest analyst target
3. DCF / Fair value
$1.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.87
Low
$11.84
High
$44.00
Mean
$29.70

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-04 main HC Wainwright & Co. Buy → Buy $23
2026-05-01 main Piper Sandler Neutral → Neutral $16
2026-04-08 init Stifel Buy → Buy $45
2026-03-16 down Jefferies Buy → Hold $15
2026-02-24 main HC Wainwright & Co. Buy → Buy $30
2026-02-02 reit HC Wainwright & Co. Buy → Buy $40
2026-01-30 reit Citizens Market Outperform → Market Outperform $40
2025-12-17 up Barclays Underweight → Equal-Weight $18
2025-11-18 init Wolfe Research — → Peer Perform —
2025-10-22 reit Guggenheim Buy → Buy $40
2025-10-21 main Barclays Underweight → Underweight $16
2025-10-21 main HC Wainwright & Co. Buy → Buy $40
2025-10-20 main Citigroup Buy → Buy $40
2025-10-20 reit JMP Securities Market Outperform → Market Outperform $40
2025-09-17 init Barclays — → Underweight $13
2025-09-16 reit HC Wainwright & Co. Buy → Buy $50
2025-09-08 reit Cantor Fitzgerald Overweight → Overweight —
2025-09-08 reit HC Wainwright & Co. Buy → Buy $50
2025-09-04 init Guggenheim — → Buy $40
2025-09-03 reit JMP Securities Market Outperform → Market Outperform $40
News
RSS: Latest SMMT news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.70
Operating Revenue
0.00
0.00
0.00
-100.00%
0.70
Operating Expense
1,094.37
+418.72%
210.98
+137.76%
88.73
+37.95%
64.33
Research And Development
537.67
+256.60%
150.78
+153.53%
59.47
+14.37%
52.00
Selling General And Administration
556.70
+824.75%
60.20
+105.71%
29.26
+9.43%
26.74
General And Administrative Expense
556.70
+824.75%
60.20
+105.71%
29.26
+9.43%
26.74
Salaries And Wages
536.70
+979.88%
49.70
+151.01%
19.80
+3.66%
19.10
Other Gand A
20.00
+90.48%
10.50
-64.12%
29.26
+9.43%
26.74
Other Operating Expenses
—
—
-0.06
+99.44%
-9.89
Total Expenses
1,094.37
+418.72%
210.98
+137.76%
88.73
+37.95%
64.33
Operating Income
-1,094.37
-418.72%
-210.98
-137.76%
-88.73
-39.47%
-63.62
Total Operating Income As Reported
—
-226.00
+62.93%
-609.65
-745.69%
-72.09
EBITDA
-1,079.39
-407.89%
-212.53
+64.48%
-598.27
-718.22%
-73.12
Normalized EBITDA
-1,094.28
-418.89%
-210.89
-137.52%
-88.79
-46.66%
-60.54
Reconciled Depreciation
0.15
+64.04%
0.09
-55.05%
0.20
-84.32%
1.26
EBIT
-1,079.54
-407.74%
-212.62
+64.47%
-598.47
-704.60%
-74.38
Total Unusual Items
14.89
+1009.10%
-1.64
+99.68%
-509.48
-3950.89%
-12.58
Total Unusual Items Excluding Goodwill
14.89
+1009.10%
-1.64
+99.68%
-509.48
-3950.89%
-12.58
Special Income Charges
0.00
+100.00%
-15.01
+97.12%
-520.91
-6051.57%
-8.47
Other Special Charges
—
15.01
-97.12%
520.91
—
Impairment Of Capital Assets
—
0.00
0.00
-100.00%
8.47
Net Income
-1,079.59
-387.81%
-221.31
+64.01%
-614.93
-680.54%
-78.78
Pretax Income
-1,079.54
-387.81%
-221.30
+64.01%
-614.93
-680.54%
-78.78
Net Non Operating Interest Income Expense
0.00
+100.00%
-8.69
+47.23%
-16.46
-469.98%
-2.89
Interest Expense Non Operating
0.00
-100.00%
8.69
-47.23%
16.46
+274.03%
4.40
Net Interest Income
0.00
+100.00%
-8.69
+47.23%
-16.46
-469.98%
-2.89
Interest Expense
0.00
-100.00%
8.69
-47.23%
16.46
+274.03%
4.40
Interest Income Non Operating
—
13.47
+29.44%
10.40
+587.57%
1.51
Interest Income
—
13.47
+29.44%
10.40
+587.57%
1.51
Other Income Expense
14.84
+1005.86%
-1.64
+99.68%
-509.73
-4053.28%
-12.27
Other Non Operating Income Expenses
-0.05
—
-0.25
-182.89%
0.30
Gain On Sale Of Security
14.89
+11.38%
13.37
+16.91%
11.44
+378.29%
-4.11
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-1,079.54
-387.81%
-221.30
+64.01%
-614.93
-680.54%
-78.78
Net Income From Continuing Operation Net Minority Interest
-1,079.59
-387.81%
-221.31
+64.01%
-614.93
-680.54%
-78.78
Net Income From Continuing And Discontinued Operation
-1,079.59
-387.81%
-221.31
+64.01%
-614.93
-680.54%
-78.78
Net Income Continuous Operations
-1,079.54
-387.81%
-221.30
+64.01%
-614.93
-680.54%
-78.78
Normalized Income
-1,094.48
-398.22%
-219.68
-108.33%
-105.45
-59.27%
-66.20
Net Income Common Stockholders
-1,079.59
-387.81%
-221.31
+64.01%
-614.93
-680.54%
-78.78
Diluted EPS
-1.44
-364.52%
-0.31
+68.69%
-0.99
-141.46%
-0.41
Basic EPS
-1.44
-364.52%
-0.31
+68.69%
-0.99
-141.46%
-0.41
Basic Average Shares
747.70
+4.06%
718.54
+15.96%
619.65
+220.50%
193.34
Diluted Average Shares
747.70
+4.06%
718.54
+15.96%
619.65
+220.50%
193.34
Diluted NI Availto Com Stockholders
-1,079.59
-387.81%
-221.31
+64.01%
-614.93
-680.54%
-78.78
Other Taxes
—
-0.31
+66.91%
-0.95
+79.08%
-4.52
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
751.18
+72.46%
435.56
+114.62%
202.95
-69.44%
664.17
Current Assets
720.30
+69.98%
423.75
+123.36%
189.71
-71.11%
656.71
Cash Cash Equivalents And Short Term Investments
713.45
+73.02%
412.35
+121.40%
186.24
-46.58%
348.61
Cash And Cash Equivalents
225.27
+114.82%
104.86
+46.81%
71.42
-79.51%
348.61
Cash Equivalents
208.90
+135.78%
88.60
+46.79%
60.36
-78.93%
286.51
Cash Financial
16.37
+0.63%
16.26
+46.94%
11.07
-82.18%
62.09
Other Short Term Investments
488.18
+58.77%
307.49
+167.81%
114.82
0.00
Receivables
—
0.56
-34.32%
0.85
-86.13%
6.12
Accounts Receivable
—
—
0.00
-100.00%
0.35
Other Receivables
—
—
—
1.50
Taxes Receivable
—
0.56
-34.32%
0.85
-85.29%
5.77
Prepaid Assets
—
—
2.44
+62.30%
1.50
Restricted Cash
0.32
-2.77%
0.33
0.00
-100.00%
300.00
Other Current Assets
6.54
-40.98%
11.08
+322.43%
2.62
+439.51%
0.49
Total Non Current Assets
30.88
+161.48%
11.81
-10.78%
13.24
+77.53%
7.46
Net PPE
21.68
+192.98%
7.40
+22.02%
6.06
+19.33%
5.08
Gross PPE
21.68
+192.98%
7.40
+4.12%
7.11
+11.40%
6.38
Accumulated Depreciation
—
-1.12
-7.29%
-1.04
+19.66%
-1.30
Properties
—
0.00
0.00
0.00
Machinery Furniture Equipment
—
1.03
+14.73%
0.90
+0.79%
0.89
Other Properties
21.68
+192.98%
7.40
+25.79%
5.88
+25.66%
4.68
Leases
—
0.32
-1.52%
0.33
-59.46%
0.81
Goodwill And Other Intangible Assets
2.00
+7.35%
1.86
-1.53%
1.89
+5.28%
1.80
Goodwill
2.00
+7.35%
1.86
-1.53%
1.89
+5.28%
1.80
Other Intangible Assets
—
—
—
—
Non Current Accounts Receivable
—
0.70
-27.22%
0.96
—
Other Non Current Assets
7.21
+182.77%
2.55
-41.05%
4.32
+649.05%
0.58
Total Liabilities Net Minority Interest
92.32
+97.22%
46.81
-62.63%
125.26
-76.70%
537.51
Current Liabilities
72.99
+74.91%
41.73
+104.50%
20.41
-47.39%
38.78
Payables And Accrued Expenses
52.39
+116.59%
24.19
+111.27%
11.45
+3.91%
11.02
Payables
20.29
+337.70%
4.64
+73.83%
2.67
+651.27%
0.35
Accounts Payable
20.29
+337.70%
4.64
+73.83%
2.67
+651.27%
0.35
Current Accrued Expenses
32.10
+64.16%
19.55
+122.63%
8.78
-17.64%
10.66
Pensionand Other Post Retirement Benefit Plans Current
14.93
+24.61%
11.98
+120.61%
5.43
-3.76%
5.64
Current Debt And Capital Lease Obligation
3.39
-10.01%
3.77
+34.03%
2.81
-86.91%
21.46
Current Debt
—
—
—
19.77
Current Capital Lease Obligation
3.39
-10.01%
3.77
+34.03%
2.81
+66.21%
1.69
Current Deferred Liabilities
—
—
—
0.00
Current Deferred Revenue
—
—
—
0.00
Other Current Liabilities
2.28
+27.05%
1.80
+150.63%
0.72
+8.31%
0.66
Total Non Current Liabilities Net Minority Interest
19.33
+280.37%
5.08
-95.15%
104.85
-78.98%
498.73
Long Term Debt And Capital Lease Obligation
17.50
+406.86%
3.45
-96.66%
103.29
-79.23%
497.30
Long Term Debt
—
—
100.00
-79.78%
494.54
Long Term Capital Lease Obligation
17.50
+406.86%
3.45
+4.95%
3.29
+19.07%
2.76
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Other Non Current Liabilities
1.83
+12.39%
1.63
+4.35%
1.56
+9.31%
1.43
Stockholders Equity
658.86
+69.48%
388.75
+400.37%
77.69
-38.66%
126.65
Common Stock Equity
658.86
+69.48%
388.75
+400.37%
77.69
-38.66%
126.65
Capital Stock
7.75
+5.12%
7.38
+5.12%
7.02
+232.56%
2.11
Common Stock
7.75
+5.12%
7.38
+5.12%
7.02
+232.56%
2.11
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
775.37
+5.12%
737.63
+5.13%
701.66
+232.40%
211.09
Ordinary Shares Number
775.37
+5.12%
737.63
+5.13%
701.66
+232.40%
211.09
Additional Paid In Capital
2,947.80
+84.44%
1,598.23
+49.87%
1,066.38
+111.26%
504.77
Retained Earnings
-2,294.16
-88.89%
-1,214.57
-22.28%
-993.26
-162.54%
-378.33
Gains Losses Not Affecting Retained Earnings
-2.54
-11.16%
-2.29
+6.66%
-2.45
-29.32%
-1.89
Other Equity Adjustments
-2.54
-11.16%
-2.29
+6.66%
-2.45
-29.32%
-1.89
Total Equity Gross Minority Interest
658.86
+69.48%
388.75
+400.37%
77.69
-38.66%
126.65
Total Capitalization
658.86
+69.48%
388.75
+118.78%
177.69
-71.40%
621.19
Working Capital
647.31
+69.44%
382.02
+125.64%
169.31
-72.60%
617.93
Invested Capital
658.86
+69.48%
388.75
+118.78%
177.69
-72.28%
640.96
Total Debt
20.89
+189.42%
7.22
-93.20%
106.10
-79.55%
518.76
Net Debt
—
—
28.57
-82.76%
165.70
Capital Lease Obligations
20.89
+189.42%
7.22
+18.35%
6.10
+36.96%
4.45
Net Tangible Assets
656.86
+69.78%
386.88
+410.41%
75.80
-39.29%
124.86
Tangible Book Value
656.86
+69.78%
386.88
+410.41%
75.80
-39.29%
124.86
Current Notes Payable
—
—
0.00
-100.00%
19.77
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-322.93
-127.25%
-142.11
-85.13%
-76.76
-84.60%
-41.58
Cash Flow From Continuing Operating Activities
-322.93
-127.25%
-142.11
-85.13%
-76.76
-84.60%
-41.58
Net Income From Continuing Operations
-1,079.59
-387.81%
-221.31
+64.01%
-614.93
-680.54%
-78.78
Depreciation Amortization Depletion
0.15
+64.04%
0.09
-55.05%
0.20
-84.32%
1.26
Depreciation
0.15
+64.04%
0.09
-55.05%
0.20
-43.27%
0.35
Amortization Cash Flow
—
0.00
0.00
-100.00%
0.91
Depreciation And Amortization
0.15
+64.04%
0.09
-55.05%
0.20
-84.32%
1.26
Amortization Of Intangibles
—
0.00
0.00
-100.00%
0.91
Other Non Cash Items
—
15.01
-97.15%
527.17
+17252.47%
3.04
Stock Based Compensation
732.42
+1336.65%
50.98
+261.36%
14.11
+18.08%
11.95
Asset Impairment Charge
0.00
0.00
-100.00%
0.47
-94.40%
8.47
Operating Gains Losses
-0.32
-239.74%
0.23
+117.09%
-1.34
-151.22%
2.62
Net Foreign Currency Exchange Gain Loss
-0.32
-239.74%
0.23
+118.60%
-1.23
-147.06%
2.62
Gain Loss On Sale Of PPE
—
—
-0.11
0.00
Change In Working Capital
31.42
+102.96%
15.48
+3099.81%
-0.52
-105.23%
9.87
Change In Receivables
—
0.54
-88.18%
4.53
-51.90%
9.41
Changes In Account Receivables
—
0.00
-100.00%
0.36
-63.18%
0.97
Change In Prepaid Assets
4.87
+166.02%
-7.37
-303.99%
3.61
-29.25%
5.11
Change In Payables And Accrued Expense
31.14
+52.28%
20.45
+5959.89%
-0.35
-115.45%
2.26
Change In Accrued Expense
15.84
-14.09%
18.44
+805.82%
-2.61
-140.87%
6.39
Change In Payable
15.30
+659.45%
2.02
-10.96%
2.26
+154.77%
-4.13
Change In Account Payable
15.30
+659.45%
2.02
-10.96%
2.26
+154.77%
-4.13
Change In Other Working Capital
0.20
+221.56%
-0.17
+53.48%
-0.36
+94.96%
-7.13
Change In Other Current Assets
-4.88
-297.37%
2.47
+172.20%
-3.42
-1691.16%
0.21
Change In Other Current Liabilities
0.08
-15.79%
0.10
0.00
0.00
Investing Cash Flow
-174.31
+15.11%
-205.34
+65.06%
-587.77
-94094.55%
-0.62
Cash Flow From Continuing Investing Activities
-174.31
+15.11%
-205.34
+65.06%
-587.77
-94094.55%
-0.62
Net PPE Purchase And Sale
-0.66
-372.66%
-0.14
-241.84%
0.10
+115.71%
-0.62
Purchase Of PPE
-0.66
-372.66%
-0.14
-8.59%
-0.13
+79.49%
-0.62
Sale Of PPE
0.00
0.00
-100.00%
0.23
0.00
Capital Expenditure
-0.66
-372.66%
-0.14
-8.59%
-0.13
+79.49%
-0.62
Net Investment Purchase And Sale
-173.65
+8.70%
-190.19
-68.53%
-112.86
0.00
Purchase Of Investment
-484.99
+28.68%
-680.03
-111.83%
-321.02
0.00
Sale Of Investment
311.34
-36.44%
489.84
+135.31%
208.16
0.00
Net Other Investing Changes
—
-15.01
+96.84%
-475.01
—
Financing Cash Flow
617.53
+61.99%
381.23
+340.66%
86.51
-86.05%
620.24
Cash Flow From Continuing Financing Activities
617.53
+61.99%
381.23
+340.66%
86.51
-86.05%
620.24
Net Issuance Payments Of Debt
0.00
+100.00%
-100.00
-305.09%
-24.69
-104.75%
520.00
Issuance Of Debt
—
0.00
0.00
-100.00%
545.00
Repayment Of Debt
0.00
+100.00%
-100.00
-305.09%
-24.69
+1.26%
-25.00
Long Term Debt Issuance
—
0.00
0.00
-100.00%
545.00
Long Term Debt Payments
0.00
+100.00%
-100.00
-305.09%
-24.69
+1.26%
-25.00
Net Long Term Debt Issuance
0.00
+100.00%
-100.00
-305.09%
-24.69
-104.75%
520.00
Net Common Stock Issuance
604.57
+26.51%
477.89
+335.69%
109.69
+9.69%
100.00
Proceeds From Stock Option Exercised
12.97
+288.96%
3.33
+56.38%
2.13
+434.34%
0.40
Net Other Financing Charges
—
—
-0.62
-299.35%
-0.15
Changes In Cash
120.29
+256.11%
33.78
+105.84%
-578.02
-200.00%
578.04
Effect Of Exchange Rate Changes
0.10
+666.67%
-0.02
-102.15%
0.84
+168.66%
-1.22
Beginning Cash Position
105.19
+47.27%
71.42
-88.99%
648.61
+803.47%
71.79
End Cash Position
225.58
+114.46%
105.19
+47.27%
71.42
-88.99%
648.61
Free Cash Flow
-323.59
-127.49%
-142.25
-85.00%
-76.89
-82.17%
-42.21
Interest Paid Supplemental Data
0.00
-100.00%
8.81
-17.31%
10.65
+2353.92%
0.43
Income Tax Paid Supplemental Data
0.00
0.00
-100.00%
0.05
0.00
Amortization Of Securities
-7.01
-171.97%
-2.58
-33.89%
-1.92
0.00
Common Stock Issuance
604.57
+26.51%
477.89
+335.69%
109.69
+9.69%
100.00
Issuance Of Capital Stock
604.57
+26.51%
477.89
+335.69%
109.69
+9.69%
100.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category